Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study identifies an important driver of inflammatory bowel disease

10

Jun 2026

Study identifies an important driver of inflammatory bowel disease

​Researchers at the Nuffield Department of Medicine, University of Oxford, together with Newcastle University's Translational and Clinical Research Institute and the Department of Immunology at Cambridge University Hospitals NHS Foundation Trust, have identified an important driver of inflammatory bowel disease (IBD).

Remote work explains part of the post-pandemic rise in mental distress

10

Jun 2026

Remote work explains part of the post-pandemic rise in mental distress

Researchers found that workers in remote jobs spent more time alone after the COVID-19 pandemic and experienced greater psychological distress than those in non-remote jobs. The effects were strongest among people living alone, suggesting that reduced everyday social contact may be an important cost of remote work.

Silver nanoparticles enable precise DNA cutting and assembly

10

Jun 2026

Silver nanoparticles enable precise DNA cutting and assembly

DNA is composed of long chains that act as the blueprint for living organisms. In genetic engineering, scientists cut DNA at specific sites and join the resulting fragments to other DNA sequences, enabling applications such as advanced crop breeding, genetic disease treatment, and the generation of animal models for drug discovery.

New study maps early genetic disruptions in Rett syndrome

10

Jun 2026

New study maps early genetic disruptions in Rett syndrome

To better understand what drives the emergence of symptoms in Rett syndrome, researchers at Baylor College of Medicine and the Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital took a closer look at brain cells in mice modeling Rett syndrome before symptoms appeared.

Automated self-driving labs accelerate the search for new medicines

10

Jun 2026

Automated self-driving labs accelerate the search for new medicines

The Acceleration Consortium (AC) at the University of Toronto and the Structural Genomics Consortium (SGC) announced today a formalized partnership to help tackle a persistent challenge in biomedicine and early drug discovery: the development of bioactive molecules with drug-like properties, advancing our understanding of human health and disease and jump-starting new drug discovery programs.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.